Use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus

Abstract

According to the invention there is provided the use of melagatran, or a pharmaceutically-acceptable derivative thereof, for the manufacture of a medicament for the treatment of Type I diabetes.

1 - 38 . (canceled)  
   
   
       39 . A method of treating Type I diabetes mellitus, which comprises administering a therapeutically-effective amount of melagatran, or a pharmaceutically-acceptable derivative thereof, to a patient in need of such treatment.  
   
   
       40 . A method as claimed in  claim 39 , wherein the derivative of melagatran is a prodrug of melagatran.  
   
   
       41 . A method as claimed in  claim 39 , wherein the derivative of melagatran is a prodrug of the formula  
       R 1 O 2 C—CH 2 —(R)Cgl-Aze-Pab-OH,  
     wherein R 1  represents linear or branched C 1-6  alkyl and the OH group replaces one of the amidino hydrogens in Pab.  
   
   
       42 . A method as claimed in  claim 41 , wherein R 1  represents methyl, ethyl, n-propyl, i-propyl or t-butyl.  
   
   
       43 . A method as claimed in  claim 41 , wherein R 1  represents ethyl.  
   
   
       44 . A method of improving insulin-independency in patients having Type I diabetes mellitus, which method comprises administering a therapeutically-effective amount of melagatran, or a pharmaceutically-acceptable derivative thereof, to a patient in need of such improvement.  
   
   
       45 . A method as claimed in  claim 44 , wherein the derivative of melagatran is a prodrug of melagatran.  
   
   
       46 . A method as claimed in  claim 44 , wherein the derivative of melagatran is a prodrug of the formula  
       R 1 O 2 C—CH 2 —(R)Cgl-Aze-Pab-OH,  
     wherein R 1  represents linear or branched C 1-6  alkyl and the OH group replaces one of the amidino hydrogens in Pab.  
   
   
       47 . A method as claimed in  claim 46 , wherein R 1  represents methyl, ethyl, n-propyl, i-propyl or t-butyl.  
   
   
       48 . A method as claimed in  claim 46 , wherein R 1  represents ethyl.  
   
   
       49 . A method of treatment of instant blood-mediated inflammatory reaction, which method comprises administering a therapeutically-effective amount of melagatran, or a pharmaceutically-acceptable derivative thereof, to a patient in need of such treatment.  
   
   
       50 . A kit of parts comprising components: 
 (a) a first component comprising melagatran or a pharmaceutically-acceptable derivative thereof; and    (b) a second component comprising cells,    which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.    
   
   
       51 . A kit as claimed in  claim 50 , wherein the cells are insulin-producing cells or precursors thereof.  
   
   
       52 . A kit as claimed in  claim 50 , wherein the cells are islets of Langerhans.  
   
   
       53 . A kit as claimed in  claim 50 , wherein the cells are precursors of insulin-producing cells which are stem cells.  
   
   
       54 . A kit as claimed in any one of  claims 50  to  53 , wherein the derivative of melagatran is a prodrug of melagatran.  
   
   
       55 . A kit as claimed in any one of  claims 50  to  53 , wherein the derivative of melagatran is a prodrug of the formula  
       R 1 O 2 C—CH 2 —(R)Cgl-Aze-Pab-OH,  
     wherein R 1  represents linear or branched C 1-6  alkyl and the OH group replaces one of the amidino hydrogens in Pab.  
   
   
       56 . A kit as claimed in  claim 55 , wherein R 1  represents methyl, ethyl, n-propyl, i-propyl or t-butyl.  
   
   
       57 . A kit as claimed in  claim 55 , wherein R 1  represents ethyl.  
   
   
       58 . A kit of parts comprising: 
 (I) one of components (a) and (b) as defined in any one of  claims 50  to  57  together with    (II) instructions to use that component in conjunction with the other of the two components.    
   
   
       59 . A method of making a kit of parts as defined in any one of  claims 50  to  57 , which method comprises bringing a component (a), as defined in any one of  claims 50  to  57 , into association with a component (b), as defined in any one of  claims 50  to  57 , thus rendering the two components suitable for administration in conjunction with each other.